查看文章

Chronic Kidney Disease (CKD) can be defined as impaired kidney function that occurs for> 3 months or more. This was indicated by a decrease in Glomerular Filtration Rate (GFR)(< 60 ml/minute/1.73 m2). CKD stage 3 has frequent hyperphosphatemia, a complication of the disease. The effects of hyperphosphatemia are the bone mineral connection and tissue calcification process. Phosphate binder was one of the therapeutic options that can be used for hyperphosphatemia. This study aims to determine the design therapy of phosphate binders used by CKD patients at hospitalization services of General Hospital Dr. Iskak Tulungagung. Observational research and retrospective. The presentation data has used descriptive of the medical record patients CKD hospitalized in the period Juli to December 2017. Phosphate binder has been used as a single therapy without combination, 130 patients (77%) used calcium carbonate, while 11 patients (7%) used calcium acetate, and of 27 patients (16%) had received switching therapy. The hyperphosphatemia therapy regimen used more calcium carbonate orally (3x500mg) in 121 patients (62%) than calcium acetate orally (1x169mg) in 16 patients (8%).